NCT07479355

Brief Summary

The ECRAN-PLASMA study aims to analyze the characteristics of patients with Mycoplasma pneumoniae or Chlamydia pneumoniae pneumonia hospitalized in intensive care units (ICU), continuous monitoring units (USC), or intensive pulmonary care units (USIP). It evaluates their management, prognosis, and macrolide resistance rates.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2024

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 15, 2024

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2024

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

March 10, 2025

Completed
1 year until next milestone

First Posted

Study publicly available on registry

March 18, 2026

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2026

Completed
Last Updated

March 18, 2026

Status Verified

March 1, 2025

Enrollment Period

Same day

First QC Date

March 10, 2025

Last Update Submit

March 16, 2026

Conditions

Pneumonia

Keywords

Intensive Care Unit (ICU)Intensive Respiratory Care Unit (USIP)Intermediate Care Unit (USC)Chlamydia pneumoniaeMycoplasma pneumoniaeInfection

Outcome Measures

Primary Outcomes (1)

  • Incidence of Severe Mycoplasma pneumoniae and Chlamydia pneumoniae Infections

    Number of patients hospitalized in ICU, USC, or USIP with a confirmed diagnosis of Mycoplasma pneumoniae or Chlamydia pneumoniae.

    From hospital admission to hospital discharge (up to 60 days)

Secondary Outcomes (10)

  • In-hospital Mortality Rate

    From hospital admission to hospital discharge (up to 60 days)

  • Length of Stay in ICU and Hospital

    From hospital admission to hospital discharge (up to 60 days)

  • Macrolide Resistance Rate

    At time of microbiological diagnosis (baseline)

  • Need for invasive mechanical ventilation

    From hospital admission to hospital discharge (up to 60 days)

  • Use of respiratory and supportive therapies

    From hospital admission to hospital discharge (up to 60 days)

  • +5 more secondary outcomes

Interventions

Infectious disease epidemiologyOTHER

evaluation of patient management, prognosis, and macrolide resistance rates in severe Mycoplasma pneumoniae and Chlamydia pneumoniae infections.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients hospitalized in Intermediate Care Units (USC), Intensive Respiratory Care Units (USIP), and Intensive Care Units (ICU) who test positive for Mycoplasma pneumoniae or Chlamydia pneumoniae

You may qualify if:

  • Screening of all patients hospitalized in Intermediate Care Units (USC), Intensive Respiratory Care Units (USIP), and Intensive Care Units (ICU)

You may not qualify if:

  • Patients under 18 years old

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medecine intensive-reanimation

Le Kremlin-Bicêtre, France

Location

MeSH Terms

Conditions

PneumoniaInfections

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 10, 2025

First Posted

March 18, 2026

Study Start

September 15, 2024

Primary Completion

September 15, 2024

Study Completion

June 15, 2026

Last Updated

March 18, 2026

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)